TECENTRIQ in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced
or mTNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease1

 

AE, adverse event; HRQoL, health-related quality of life; mTNBC, metastatic triple-negative breast cancer; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.

 

References:

  1. TECENTRIQ Summary of Product Characteristics.

 

RXUKATEZ00519.
Date of preparation: September 2019.